Clinical Trial Update: Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating PEGPH20 with cisplatin and gemcitabine, with or without atezolizumab, in previously untreated unresectable/metastatic cholangiocarcinom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Cholangiocarcinoma Extrahepatic
• Cholangiocarcinoma Intrahepatic
• Gallbladder Adenocarcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• CISPLATIN (cisplatin)
• Gemcitabine (Gemcitabine)
• PEGPH20 (pegylated hyaluronidase)

Snippet

Sponsor: Halozyme Therapeutics | Conditions: Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Intrahepatic | Phase 1 | Status: TERMINATED | Results posted: 2020-02-07